Literature DB >> 12180712

The concept of disease modification in spondyloarthropathy.

Helena Marzo-Ortega, Paul Emery, Dennis McGonagle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12180712

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  8 in total

Review 1.  Advances in the understanding of entheseal inflammation.

Authors:  Dennis McGonagle; Michael Benjamin; Helena Marzo-Ortega; Paul Emery
Journal:  Curr Rheumatol Rep       Date:  2002-12       Impact factor: 4.592

2.  How to diagnose axial spondyloarthropathy early.

Authors:  N Barkham; H Marzo-Ortega; D McGonagle; P Emery
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

3.  Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis.

Authors:  Rik J U Lories; Inge Derese; Frank P Luyten
Journal:  J Clin Invest       Date:  2005-05-12       Impact factor: 14.808

4.  Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease.

Authors:  Victoria Navarro-Compán; Virginia Moreira; Rafael Ariza-Ariza; Blanca Hernández-Cruz; Carmen Vargas-Lebrón; Federico Navarro-Sarabia
Journal:  Clin Rheumatol       Date:  2011-03-04       Impact factor: 2.980

Review 5.  Late-onset ankylosing spondylitis and related spondylarthropathies: clinical and radiological characteristics and pharmacological treatment options.

Authors:  Eric Toussirot; Daniel Wendling
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

6.  Parathyroid hormone is a determinant of serum Dickkopf-1 levels in ankylosing spondylitis.

Authors:  Giovanni Orsolini; Giovanni Adami; Maurizio Rossini; Francesco Ghellere; Cristian Caimmi; Angelo Fassio; Luca Idolazzi; Davide Gatti; Ombretta Viapiana
Journal:  Clin Rheumatol       Date:  2018-07-11       Impact factor: 2.980

7.  Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48.

Authors:  I-H Song; K G Hermann; H Haibel; C E Althoff; D Poddubnyy; J Listing; A Weiss; B Freundlich; M Rudwaleit; J Sieper
Journal:  Ann Rheum Dis       Date:  2011-05-08       Impact factor: 19.103

8.  Vasoactive Intestinal Peptide in Early Spondyloarthritis: Low Serum Levels as a Potential Biomarker for Disease Severity.

Authors:  Iria V Seoane; Eva Tomero; Carmen Martínez; Rosario Garcia-Vicuña; Yasmina Juarranz; Amalia Lamana; Elena Ocón; Ana M Ortiz; Nieves Gómez-León; Isidoro González-Álvaro; Rosa P Gomariz
Journal:  J Mol Neurosci       Date:  2015-02-25       Impact factor: 3.444
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.